Sanofi SA has expanded a collaboration with Innate Pharma SA giving it access to new assets in the field of natural kill (NK) cell antibody development. The French multinational has been working with Innate since 2016 and will now have rights to a programme targeting an immune checkpoint molecule known as B7H3 which is overexpressed in a number of solid tumours. Sanofi will also have an option to add up to two additional molecules to its repertoire of cancer targets.
Germany-based BioNTech SE, which together with Pfizer Inc commercialised the first Covid-19 vaccine, has entered into a partnership with the UK government to research and develop mRNA vaccines for other diseases. The multi-year collaboration will include the development of vaccines for cancer and infectious diseases. For cancer, the goal is to be able to provide personalised cancer therapies for up to 10,000 patients by the end of 2030, either in clinical trials or as authorised treatments.
Ipsen SA has announced a merger agreement with Albireo Pharma Inc which will give it a marketed product for the treatment of rare diseases affecting the liver. The acquisition is expected to provide immediate revenue from sales of Albireo’s lead drug Bylvay (odevixibat). However, given ongoing research and developments costs, it will be dilutive to Ipsen’s operating profit until the end of 2024.
AstraZeneca Plc is taking steps to strengthen its position in therapies for cardiovascular and and kidney diseases with the acquisition of CinCor Pharma Inc, a US based company whose lead product, baxdrostat, is in clinical development for blood pressure lowering. The transaction is expected to create new opportunities for treating uncontrolled hypertension as well as chronic kidney disease. In particular, baxdrostat could be combined with Farxiga, an approved medicine for diabetes, heart failure and kidney disease, AstraZeneca said on 9 January.
GSK Plc is to develop oligonucleotide therapeutics under a new collaboration with the genetic medicines company Wave Life Sciences Ltd. The agreement, which includes an upfront payment of $170 million in cash and equity as well as future milestone payments, involves the discovery and development of medicines based on genetic targets.
The oligonucleotide medicines are short DNA or RNA molecules that can modulate RNA through several mechanisms. The primary function of RNA is to create proteins via translation. The Wave technology is capable of editing, splicing and silencing RNA.
CureVac NV and its partner GSK Plc have reported promising preliminary data from ongoing Phase 1 studies of vaccine candidates directed against both Covid-19 and influenza. The experimental medicines are based on messenger RNA. The results showed that vaccine candidates using a modified second-generation mRNA backbone produced promising immunogenicity and reactogenicity profiles in both indications. The modified vaccines are directed against specific antigens.
Lecanemab, a monoclonal antibody drug to treat Alzheimer’s disease, was given an accelerated approval by the US Food and Drug Administration on 6 January, based on evidence that it reduced amyloid plaque, a marker for the disease. Known commercially as Leqembi, the drug is only the second antibody treatment to be given a preliminary authorisation to treat the disease, which is an irreversible, progressive brain disorder affecting millions of people. The first was Aduhelm (aducanumab), which also targets amyloid plaque.
The developers of the first chimeric antigen receptor (CAR) T cell therapies are to merge their assets under a deal that they say will speed up manufacturing and create new opportunities for treating solid tumours. The deal involves the acquisition of Tmunity Therapeutics Inc of Philadelphia, US, by Kite Pharma, a business unit of Gilead Sciences Inc. The financial terms of the transaction were not disclosed.
Switzerland-based MetrioPharm AG has reported top-line data for a candidate treatment for Covid-19, showing that the compound is as effective as two approved antiviral medicines for the disease. The drug, MP1032, is a small molecule macrophage metabolic modulator which targets activated macrophages. It acts by normalising oxidation-reduction reactions at a cellular level which is essential for the body’s immune response to infections and autoimmune and inflammatory diseases.
A second Phase 3 trial of ensifentrine, a candidate product for chronic obstructive pulmonary disease (COPD), has met its primary endpoint, paving the way for a regulatory submission in the US in the first half of 2023, the developer Verona Pharma Plc announced on 20 December. Ensifentrine is a dual inhibitor of the enzymes phosphodiesterase 3 and 4, a mode of action that enables it to combine both bronchodilator and anti-inflammatory effects in a single compound.